Maravai LifeSciences (NASDAQ:MRVI) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of Maravai LifeSciences (NASDAQ:MRVI) from a hold rating to a buy rating in a research note issued to investors on Saturday morning.

Other equities research analysts have also recently issued reports about the company. Wells Fargo & Company lifted their price objective on Maravai LifeSciences from $5.50 to $6.50 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Weiss Ratings upgraded shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $6.00 target price on shares of Maravai LifeSciences in a research note on Friday, May 8th. Finally, UBS Group reiterated a “reduce” rating on shares of Maravai LifeSciences in a report on Wednesday, June 3rd. Two investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $6.25.

Maravai LifeSciences Stock Performance

Shares of NASDAQ:MRVI opened at $5.70 on Friday. The business has a fifty day moving average of $6.08 and a 200-day moving average of $4.45. The firm has a market cap of $1.48 billion, a PE ratio of -10.96 and a beta of 0.63. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.96 and a current ratio of 4.05. Maravai LifeSciences has a twelve month low of $2.28 and a twelve month high of $7.44.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02. The firm had revenue of $51.44 million for the quarter, compared to analyst estimates of $48.67 million. Maravai LifeSciences had a negative return on equity of 15.70% and a negative net margin of 37.07%. On average, equities research analysts predict that Maravai LifeSciences will post -0.2 EPS for the current fiscal year.

Insider Activity at Maravai LifeSciences

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total transaction of $126,500.00. Following the sale, the general counsel owned 360,767 shares of the company’s stock, valued at $1,825,481.02. This trade represents a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.49% of the stock is currently owned by corporate insiders.

Institutional Trading of Maravai LifeSciences

A number of large investors have recently bought and sold shares of MRVI. Wellington Management Group LLP bought a new position in Maravai LifeSciences in the fourth quarter valued at approximately $7,670,000. General American Investors Co. Inc. increased its position in shares of Maravai LifeSciences by 1,062.2% during the fourth quarter. General American Investors Co. Inc. now owns 1,585,316 shares of the company’s stock worth $5,152,000 after acquiring an additional 1,448,907 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Maravai LifeSciences by 308.7% during the fourth quarter. Millennium Management LLC now owns 1,797,052 shares of the company’s stock worth $5,840,000 after acquiring an additional 1,357,349 shares during the period. First Eagle Investment Management LLC raised its holdings in shares of Maravai LifeSciences by 299.0% during the fourth quarter. First Eagle Investment Management LLC now owns 1,799,336 shares of the company’s stock worth $5,848,000 after acquiring an additional 1,348,405 shares during the period. Finally, Marshall Wace LLP lifted its position in Maravai LifeSciences by 52.3% in the 4th quarter. Marshall Wace LLP now owns 2,000,278 shares of the company’s stock valued at $6,501,000 after acquiring an additional 687,253 shares in the last quarter. 50.25% of the stock is owned by institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.